429 filings
Page 10 of 22
8-K
4dgbtev
7 Aug 19
Hepion Pharmaceuticals Welcomes Dr. Stephen Harrison to its Scientific Advisory Board
1:11pm
8-K
gle 97vhud8h2l
31 Jul 19
Other Events
1:41pm
8-K
augfodz
30 Jul 19
Hepion Pharmaceuticals Receives FDA Authorization to Proceed with IND Opening Study of CRV431 for NASH
4:49pm
8-K
secw01w9yo23hvja4t
23 Jul 19
Amendments to Articles of Incorporation or Bylaws
8:00am
8-K
xh9o9dxfi qdr
20 Jun 19
ContraVir Pharmaceuticals, Inc. Announces Pricing of $15.6 Million Public Offering
4:30pm
424B4
skypp4a91mt3hu9kqvc
19 Jun 19
Prospectus supplement with pricing info
5:25pm
EFFECT
kuubnw or76pili5
18 Jun 19
Notice of effectiveness
12:15am
8-K
kodssmzcpey29cz
17 Jun 19
Compelling Positive Results Reported from Human Liver Experiments with ContraVir Pharmaceuticals’ NASH Drug Candidate
11:18am
CORRESP
egjf22v
14 Jun 19
Correspondence with SEC
12:00am
RW WD
6254a9k5xv9f
13 Jun 19
Withdrawal of registration withdrawal request
4:36pm
RW
xumz7b9
13 Jun 19
Registration withdrawal request
3:30pm
CORRESP
domkqd8
13 Jun 19
Correspondence with SEC
12:00am
8-K/A
c8ar7ok 9nwb
12 Jun 19
Other Events
10:56am
CORRESP
tx561n lusvt
12 Jun 19
Correspondence with SEC
12:00am
8-K
ey9tik7 6uu
11 Jun 19
ContraVir Pharmaceuticals Announces Publication of CRV431 Data from
12:33pm
8-K
hwhy7q5
11 Jun 19
Regulation FD Disclosure
9:31am
8-K
sxiq dbq6bqb5j
6 Jun 19
ContraVir Pharmaceuticals Sets the Stage for CRV431 Development in NASH with Positive Results from Second Model of Liver Fibrosis
11:28am
CORRESP
64j14rv2iltr5rr 2zli
5 Jun 19
Correspondence with SEC
12:00am